Oscotec Inc.

Translating science into medicine
회원가입
PRESS
  1. No Image 03Mar
    by

    Other news to note for March 2, 2021

  2. No Image 15Sep
    by

    Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease

  3. No Image 27Feb
    by

    Oscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease

  4. No Image 01Jun
    by

    Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448, a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018

  5. No Image 01Jun
    by

    "ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC"

  6. No Image 01Jun
    by

    Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech

  7. No Image 01Jun
    by

    Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study

  8. No Image 01Jun
    by

    Yuhan to start phase-3 trial on lung cancer drug Lazertinib

  9. No Image 01Jun
    by

    Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC

  10. No Image 01Jun
    by

    Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations

  11. No Image 01Jun
    by

    More than half of Korean biopharma firms view R&D investments as assets.

  12. No Image 01Jun
    by

    Genosco gears up for IPO

Board Pagination Prev 1 2 3 Next
/ 3
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
서버에 요청 중입니다. 잠시만 기다려 주십시오...